CTOs on the Move

CutisPharma

www.cutispharma.com

 
CutisPharma is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

Touchstone Health Services

Touchstone partners with individuals, families, schools and other service providers to deliver the optimal continuum of health, education, social services

Groupe Parima

Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Velocity Clinical Research

Velocity Clinical Research, headquartered in Durham, NC, is a leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. The company has 18 sites across 12 US States. We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 5500 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality.